p-Amidobenzylethers in drug delivery agents
First Claim
Patent Images
1. A compound of the formula:
-
BZ-X—
WwDwherein;
D is a drug moiety;
B is a blocking group;
Z is an amino acid or a peptide residue;
X is an aminobenzyl ether self-immolative group;
W is an optional second self-immolative group;
w is an integer of 0 or 1;
wherein X—
W forms an aminobenzyl ether when w is 1, and X-D forms an aminobenzyl ether when w is 0.
2 Assignments
0 Petitions
Accused Products
Abstract
Compounds of the formulae
LAn-Z-X—WwD and BZ-X—WwD
wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and/or excipient, and methods of delivery the drug D via the compounds.
-
Citations
38 Claims
-
1. A compound of the formula:
-
BZ-X—
WwDwherein; D is a drug moiety; B is a blocking group; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative group; W is an optional second self-immolative group; w is an integer of 0 or 1; wherein X—
W forms an aminobenzyl ether when w is 1, and X-D forms an aminobenzyl ether when w is 0.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
3. A compound of claim 1, represented by the following formula:
-
4. A compound of claim 2 wherein the O of —
- O-D is bonded to a carbon that forms an aromatic ring of D.
-
5. A compound of claim 4 wherein the drug is 1,2,9,9a-tetra-hydro-cyclo-propa[c]benz[e]indol-4-one (CBI) conjugated to a minor groove binder.
-
6. A compound of claim 4 wherein the drug is cyclopropapyrroloindole (CPI) conjugated to a minor groove binder.
-
7. A compound of claim 4 wherein the drug is 1,2,9,9a-tetra-hydro-cyclo-propa[c]pyrido[3,2-e]indol-4-one (CPyI) conjugated to a minor groove binder.
-
8. A compound of claim 4 wherein the drug is selected from:
- ((S)—
N-[2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b;
4,3-b′
]dipyrrol-3(2-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2-benzofurancarboxamide) (U-76,073);
seco-adozelesin;
bizelesin;
1,2,9,9a-tetra-hydro-cyclo-propa[c]benz[e]indol-4-one-trimethoxyindole (CBI-TMI);
duocarmycin C2;
duocarmycin B2;
(Benzo(1,2-b;
4,3-b′
)dipyrrole-3(2H)-carboxamide, 7-((1,6-dihydro-4-hydroxy-5-methoxy-7-((4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa(c)pyrrolo(3,2-e)indol-2(1H)-yl)carbonyl)benzo(1,2-b;
4,3-b′
)dipyrrol-3(2H)-yl)carbonyl)-1,6-dihydro-4-hydroxy-5-methoxy-, (7bR)—
) (seco-CC-1065);
pancratistatin;
carminomycin;
streptonigrin;
zorubicin;
elliptinium acetate;
mitoxantrone;
daunorubicin;
phenol mustard;
doxorubicin;
etoposide, combretastatin A-4, and 7-ethyl-10-hydroxycamptothecin (SN-38).
- ((S)—
-
9. A compound of claim 4 wherein the O of —
- O-D is bonded to an aliphatic carbon of D.
-
10. A compound of claim 9 in which the drug is auristatin E.
-
11. A compound of claim 2 wherein the H of H—
- O-D has a pKa of 16 or less.
-
12. A compound of claim 3 wherein T is NH or N(lower alkyl).
-
13. A compound of claim 3 wherein T is O or S.
-
14. A compound of claim 12 wherein the drug is selected from 5-amino-1,2,9,9a-tetra-hydro-cyclopropa[c]benz[e]indol-4-one (CBI) conjugated to a minor groove binder;
- 5-amino-cyclopropapyrroloindole (CPI) conjugated to a minor groove binder, and 5-amino-1,2,9,9a-tetra-hydro-cyclopropa[c]pyrido[3,2-e]indol-4-one (CPyI) conjugated to a minor groove binder.
-
15. A compound of claim 12 wherein the drug is an amino containing drug moiety selected from the group consisting of mitomycin-C, mitomycin-A, daunorubicin, doxorubicin, N-(5,5-diacetoxypentyl)doxorubicin, aminopterin, actinomycin, bleomycin, 9-amino camptothecin, N8-acetyl spermidine, 1-(2 chloroethyl)-1,2-dimethanesulfonyl hydrazide, tallysomycin, and derivatives thereof.
-
16. A compound of claim 13 wherein the drug is auristatin E.
-
17. A compound of claim 13 wherein the drug is a hydroxyl-containing moiety selected from the group consisting of:
- etoposide, camptothecin, taxol, esperamicin, 1,8-dihydroxy-bicyclo[7.3.1]trideca-4,9-diene-2,6-diyne-13-one, anguidine, doxorubicin, morpholino-doxorubicin, N-(5,5-diacetoxypentyl)doxorubicin, vincristine, vinblastine and derivatives thereof.
-
18. A compound of claim 13 wherein the drug is a sulfhydryl-containing moiety selected from the group consisting of esperamicin, 6-mercaptopurine, and derivatives thereof.
-
19. A compound of claim 2 wherein m is 0.
-
20. A compound of claim 3 wherein m is 0.
-
21. A compound of claim 2 wherein m is 1 and the substituent is an electron-withdrawing group selected from F, Cl, Br, CN, CF3, CONH2, CHO, CO2CH3, COCH3, NHCOCH3, NO2, and sulfonyl groups.
-
22. A compound of claim 2 wherein m is 1 and the substituent is an electron-withdrawing group selected from F, Cl, Br, CN, CF3, CONH2, CHO, CO2CH3, COCH3, NHCOCH3, NO2, and sulfonyl groups.
-
23. A compound of claim 2 wherein Z is a dipeptide or a tripeptide.
-
24. A compound of claim 3 wherein Z is a dipeptide or a tripeptide.
-
25. A compound of claim 2 wherein Z is valine-citrulline.
-
26. A compound of claim 3 wherein Z is valine-citrulline.
-
27. A compound of claim 2 wherein Z is phenylalanine-lysine.
-
28. A compound of claim 3 wherein Z is phenylalanine-lysine.
-
29. A compound of claim 2 wherein
-
30. A compound of claim 3 wherein
-
31. A compound of claim 2 wherein B is a carbobenzoxy protecting group.
-
32. A compound of claim 3 wherein B is a carbobenzoxy protecting group.
-
33. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
-
34. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier, diluent or excipient.
-
35. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier, diluent or excipient.
-
36. A compound of claim 1 wherein D is cytotoxic.
-
37. A compound of claim 2 wherein HO-D is cytotoxic.
-
38. A compound of claim 3 wherein HT-D is cytotoxic.
Specification